Our broad pipeline includes multiple targeted therapies that harness the immune system and target specific molecular pathways.
*Combination trials may repeat in the pipeline to accurately display the status of each asset.
APL-101 is known as PLB1001 in China and partnered with Beijing Pearl Biotechnology
APL-103 is known as ES-072 in China and partnered with Zhejiang Bossan Pharmaceutical Co.
APL-501 is known as GB226 in China and partnered with Genor Biopharma
APL-502 is known as TQ-B2450 in China and partnered with Chia Tai TianQing